Summer 2022: Updated Clinical Research on Alveolar Soft Part Sarcoma

Below are links to eighteen publications describing clinical studies of ASPS with novel treatments as well as preclinical information on ASPS.

The ASPS community is thankful to all the Principle Investigators, Oncologists and Researchers who are working with us to find a cure for ASPS! 

1. Anlotinib with Toripalimab for ASPS Therapy
2. Complete Response of Metastatic ASPS Treated by Combined Immune Checkpoint Inhibitors
3. Review of Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
4. Response of ASPS to Pembrolizumab After Carbon Ion Radiation Therapy
5. Activity of PD-1 Inhibitor Combined with Anti-Angiogenic Therapy in Advanced Sarcoma
6. Review of Stereotactic Radiosurgery in ASPS Brain Metastases
7. The Current Management of ASPS
8. Advances in the Management of ASPS
9. Target Therapy for Metastatic ASPS: A Retrospective Study with 47 Cases
10. Gene of the month: TFE 3
11. Analysis of Phase II Trials: PD1/PD-L1 Targeting in Advanced Soft Tissue Sarcomas
12. Cediranib Phase II Study in Children with Metastatic ASPS
13. Cediranib in ASPS (CASPS): A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
14. Efficacy and Safety of Apatinib in ASPS
15. Axitinib plus pembrolizumab in Patients with Advanced Sarcomas Including ASPS
16. Effective Treatment of ASPS with sunitinib
17. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft- Tissue Sarcoma 
18. Activity and Safety of Crizotinib in ASPS phase II trial